おかえりなさい
アカウント登録
siteでログインする
siteで登録する
受信トレイを確認する
Melinta Therapeutics
About
Melinta Therapeutics is an antibiotics-focused company that develops and commercializes antibiotics to overcome drug-resistant infections.
- 251 - 500
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $3M
- Industries
- Biotechnology,Emergency Medicine,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2000
- Number Of Employee
- 251 - 500
- Operating Status
- Active
Melinta Therapeutics is an antibiotics-focused company. The company’s mission is to discover, develop and commercialize urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is focused on its ongoing research program to develop a new class of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause the majority of serious hospital infections and patient deaths. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 10, 2015 | Post-IPO Equity | $67M | 1 |
Malin Corporation
|
— | Detail |
| Feb 9, 2015 | Post-IPO Debt | $30M | 1 | — | — | Detail |
| Feb 7, 2012 | Post-IPO Equity | $3M | 1 |
Sanofi
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Malin Corporation
|
Yes | Post-IPO Equity |
|
Sanofi
|
Yes | Post-IPO Equity |
Hercules Capital
|
— | Post-IPO Debt |
